<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Intervened</title>
	<atom:link href="http://www.tapanray.in/tag/intervened/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Supreme Court Intervened…But ‘Price Control’ needs striking a right balance between ‘Affordability’ and ‘Availability’ of medicines for Patients’ Sake</title>
		<link>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients</link>
		<comments>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/#comments</comments>
		<pubDate>Mon, 08 Oct 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[balance]]></category>
		<category><![CDATA[between]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intervened]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[medicines for Patients’ Sake]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1084</guid>
		<description><![CDATA[On October 3, 2012, the Supreme Court bench of Justice GS Singhvi and Justice SJ Mukhopadhayareportedly asked the government not to disturb the existing price control mechanism while including all medicines featuring  in the National List of Essential Medicines 2011 (NLEM &#8230; <a href="http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-intervenedbut-price-control-needs-striking-a-right-balance-between-affordability-and-availability-of-medicines-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
